Adenosine reduces cardiac TNF-α production and human myocardial injury following ischemia-reperfusion

Journal of Surgical Research

Volumn 76, Issue 2, 1998, Pages 117-123

  Cain, Brian S ^a   Meldrum, Daniel R ^a   Dinarello, Charles A ^a   Meng, Xianzhong ^a   Banerjee, Anirban ^a   Harken, Alden H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cardiac preconditioning; Inflammation; Rat; TNF binding protein; Trabeculae

Indexed keywords

ADENOSINE; TUMOR NECROSIS FACTOR ALPHA;

ALLOGRAFT; CONFERENCE PAPER; DRUG RECEPTOR BINDING; GRAFT REJECTION; HEART GRAFT; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HIGH ENERGY PHOSPHATE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REPERFUSION INJURY;

EID: 0032078585     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1998.5304     Document Type: Conference Paper

References (53)

1. Meldrum D. R. Tumor necrosis factor in the heart. Am. J. Physiol. 274:1998;R577.
2. Latini R., Bianchi M., Correale E., Dinarello C. A., Fantuzzi G., Fresco C., Maggoini A. P., Mengozzi M., Romano S., Shapiro L. Cytokines in acute myocardial infarction: Selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin 1 receptor antagonist. J. Cardiovasc. Pharmacol. 23:1994;1.
3. Levine B., Kalman J., Mayer L., Fillit H., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Eng. J. Med. 323:1990;236.
4. Torre-Amione G., Kapadia S., Lee J., Bies R. D., Lebovitz R., Mann D. L. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 92:1995;1487.
5. Oral H., Kapadia S., Nakano M., Torre-Amione G., Lee J., Lee-Jackson D., Young J. B., Mann D. L. Tumor necrosis factor alpha and the failing human heart. Clin. Cardiol. 8:1995;IV20.
6. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., Zentella A., Albert J. D., Shires G. T., Cerami A. Shock and tissue injury induced by recombinant human cachectin. Science. 234:1986;470.
7. Finkel M. S., Oddis C. V., Jacob T. D., Watkins S. C., Hattler B. G., Simmons R. L. Negative notropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387.
8. Murray D. R., Freeman G. L. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ. Res. 78:1995;154.
9. Kapadia S., Lee J., Torre-Amione G., Birdsall H. H., Ma T. S., Mann D. L. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J. Clin. Invest. 96:1995;1042.
10. Parmely M. J., Zhou W. W., Edwards C. K., Borcherding D. R., Silverstein R., Morrison D. C. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J. Immunol. 151:1993;389.
11. Bowlin T. L., Borcherding D. R., Edwards C. K., McWhinney C. D. Adenosine A3 receptor agonists inhibit murine macrophage tumor necrosis factor-alpha production in vitro and in vivo. Cell. Mol. Biol. 43:1997;345.
12. Hasko G., Sczabo C., Nemeth Z. H., Kvetan V., Pastores S. M., Vizi E. S. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264. J. Immunol. 157:1996;4634.
13. Ritchie P. K., Spangelo B. L., Krzymowski D. K., Rossiter T. B., Kurth E., Judd A. M. Adenosine increases interleukin 6 and deceases tumour necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages. Cytokine. 9:1997;187.
14. Meldrum D. R., Cain B. S., Cleveland J. C., Meng X., Ayala A., Harken A. H. Adenosine decreases post-ischemic myocardial TNFα: Implications for preconditioning and transplantation. Immunology. 92:1997;472.
15. Fox A. C., Reed G. E., Meilman H., Silk B. B. Release of nucleosides from canine and human hearts as an index of prior ischemia. Am. J. Cardiol. 43:1979;52.
16. Vrobel T. R., Jorgensen C. R., Bache R. J. Myocardial lactate and adenosine metabolite production as indicators of excercise-induced myocardial ischemia in the dog. Circulation. 66:1982;554.
17. Cleveland J. C., Meldrum D. R., Rowland R. T., Sheridan B. C., Banerjee A., Harken A. H. The obligate role of protein kinase C in mediating clinically accessible cardiac preconditioning. Surgery. 120:1996;345.
18. Cleveland J. C., Meldrum D. R., Rowland R. T., Banerjee A., Harken A. H. Adenosine preconditioning of human myocardium is mediated through KATP channel activation. Surg. Forum. XLVII:1996;209.
19. +. J. Mol. Cell. Cardiol. 29:1997;175.
20. Cleveland J. C., Wollmering M. M., Meldrum D. R., Rowland R. T., Rehring T. F., Sheridan B. C., Harken A. H., Banerjee A. Ischemic preconditioning in human and rat ventricle. Am. J. Physiol. 271:1996;H1786.
21. Meldrum D. R., Cleveland J. C., Sheridan B. C., Rowland R. T., Banerjee A., Harken A. H. Differential effects of adenosine preconditioning on the postischemic rat myocardium. J. Surg. Res. 65:1996;159.
22. Meldrum D. R., Cleveland J. C., Rowland R. T., Banerjee A., Harken A. H., Meng X. Early and delayed preconditioning: Differential mechanisms and additive protection. Am. J. Physiol. 273:1997;H725.
23. Meldrum D. R., Cleveland J. C., Meng X., Sheridan B. C., Gamboni F., Cain B. S., Harken A. H., Banerjee A. Protein kinase C isoform diversity in preconditioning. J. Surg. Res. 69:1997;183.
24. Cain B. S., Meldrum D. R., Cleveland J. C., Meng X., Banerjee A., Harken A. H. The alpha and beta isoforms of protein kinase C mediate the human myocardial contractile response to exogenous calcium. Surg. Forum. XLVIII:1997;335.
25. Cain B. S., Meldrum D. R., Meng X., Shames B. D., Banerjee A., Harken A. H. Calcium preconditioning in human myocardium. Ann. Thorac. Surg. 1998.
26. Cleveland J. C., Meldrum D. R., Cain B. S., Banerjee A., Harken A. H. Oral sulfonylurea agents prevent ischemic preconditioning in human myocardium. Circulation. 96:1997;29.
27. 1. Am. J. Physiol. 273:1997;H902.
28. Su X., Zhou T., Yang P., Edwards C. K., Mountz J. D. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor. Arthritis Rheum. 41:1998;139.
29. Brown J. M., Grosso M. A., Terada L. S., Whitman G., Banerjee A., White C. W., Harken A. H., Repine J. E. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc. Natl. Acad. Sci. USA. 86:1989;2516.
30. Engler R. L., Yellon D. M. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease: Time for reconsideration. Circulation. 94:1996;2297.
31. Gurevitch J., Frolkis I., Yuhas Y., Paz Y., Matsa M., Mohr R., Yakirevich V. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J. Am. Coll. Cardiol. 28:1996;247.
32. Chandrasekar B., Colston J. T., Freeman G. L. Induction of proinflammatory cytokine and antioxidant enzyme gene expression following brief myocardial ischemia. Clin. Exp. Immunol. 108:1997;346.
33. Squadrito F., Altavilla D., Zingarelli B., Ioculano M., Calapai G., Campo G. M., Miceli A., Caputi A. P. Tumor necrosis factor incolvement in ischaemia-reperfusion. Eur. J. Pharmacol. 237:1993;223.
34. Oral H., Dorn G. W., Mann D. L. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mamalian cardiac myocyte. J. Biol. Chem. 272:1997;4836.
35. VanderPoll T., Romjin J. A., Endert E., Borm J. J. J., Buller H. R., Sauerwein H. P. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am. J. Physiol. 261:1991;E457.
36. Vincent J. L., Bakker J., Marecaux G., Schandene L., Kahn R. J., Dupont E. Administration of anti-TNF antibody improves left ventricular function in septic shock patients: Results of a pilot study. Chest. 101:1992;810.
37. Cain B. S., Meldrum D. R., Harken A. H., McIntyre R. C. Physiologic basis for anti-cytokine clinical trials in the treatment of sepsis. J. Am. Coll. Surg. 186:1998;337.
38. Barnes C. R., Mandell G. L., Carper H. T., Luong S., Sullivan G. W. Adenosine modulation of tumor necrosis factor-alpha-induced nuetrophil activation. Biochem. Pharmacol. 50:1995;1851.
39. Bullough D. A., Magill M. J., Firestein G. S., Mullane K. M. Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myoctes. J. Immunol. 155:1995;2579.
40. 2+2+. FEBS Lett. 376:1995;24.
41. Dinarello C. A. Biologic basis for Interleukin-1 in disease. Blood. 87:1996;2095.
42. Meldrum D. R., Cleveland J. C., Sheridan B. C., Rowland R. T., Banerjee A., Harken A. H. Cardiac surgical implications of calcium dyshomeostasis in the heart. Ann. Thorac. Surg. 61:1996;1273.
43. Last-Barney K., Homan C. A., Faanes R. B., Merluzzi V. J. Synergistic and overlapping activities of tumor necrosis factor-alpha and IL-1. J. Immunol. 141:1988;527.
44. Sabbadini R. A., Betto R., Teresi A., Fachechi-Cassano G., Salviati G. The effects of sphingosine on sarcoplasmic reticulum calcium release. J. Biol. Chem. 267:1992;15475.
45. Brady A. J. B., Poole-Wilson P. A., Harding S. E., Warren J. B. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxinemia. Am. J. Physiol. 263:1992;H1963.
46. Schulz R., Panas D. L., R.Catena, Moncada S., Olley P. M., Lopaschuk G. D. The role of nitric oxide in cardiac depression induced by interleukin-1β and tumor necrosis factor-α Br. J. Pharmacol. 114:1995;27.
47. Habib F. M., Springall D. R., Davies G. J., Oakley C. M., Yacoub M. H., Polak J. M. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet. 347:1996;1151.
48. Yokoyama T., Vaca L., Rossen R. D., Durante W., Hazarika P., Mann D. L. Cellular basis of the negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J. Clin. Invest. 92:1993;2303.
49. Meng X., Ao L., Brown J. M., Fullerton D. A., Banerjee A., Harken A. H. Nitric oxide synthase is not involved in cardiac contractile dysfunction in a rat model of endotoxinemia without shock. Shock. 7:1997;111.
50. i. Am. J. Physiol. 271:1996;H1449.
51. Mathias S., Dressler K. A., Kolesnik R. N. Characterization of a ceramide-activated protein kinase: Stimulation by tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA. 88:1991;10009.
52. Dressler K. A., Mathias S., Kolesnick R. N. Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system. Science. 255:1992;1715.
53. Weigman K., Schutze S., Kampen E., Himmler A., Machleidt T., Kronke M. Human 55-kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J. Biol. Chem. 267:1992;17997.